Impact of UGT1A1 gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS clinical trials group study A5202

Journal of Infectious Diseases

Volumn 207, Issue 3, 2013, Pages 420-425

  Ribaudo, Heather J ^a   Daar, Eric S ^c   Tierney, Camlin ^a   Morse, Gene D ^d   Mollan, Katie ^a   Sax, Paul E ^b   Fischl, Margaret A ^e   Collier, Ann C ^f   Haas, David W ^g  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atazanavir; Gilbert syndrome; HIV therapy; pharmacogenetics; UGT1A1

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLUCURONOSYLTRANSFERASE 1A1; PLACEBO; BILIRUBIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BILIRUBIN BLOOD LEVEL; CAUCASIAN; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GILBERT DISEASE; HISPANIC; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEGRO; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT REFUSAL; UDP GLUCOSYLTRANSFERASE 1A1 GENE; BLACK PERSON; DRUG SUBSTITUTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UGT1A1 GENE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BILIRUBIN; GENETIC VARIATION; GENOTYPE; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HIV-1; HUMANS; JAUNDICE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR;

EID: 84872006714     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis690     Document Type: Article

References (14)

1. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. New Engl J Med 1995; 333:1171-5.
2. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347:578-81.
3. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33:1729-39.
4. Cleijsen RM, van de Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemo 2007; 60:897-900.
5. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-55.
6. Torti C, Lapadula G, Antinori A, et al. Hyperbilirubinemia during atazanavir treatment in 2404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection 2009; 37:244-9.
7. Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatmentnaive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010; 51:855-64.
8. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-56.
9. McDonald C, Uy J, Hu W, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE Study. AIDS Patient Care STDs 2012; 25:259-64.
10. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192:1381-6.
11. Lubomirov R, Colombo S, di Iulio J, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011; 203: 246-57.
12. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-40.
13. Haas DW, Wilkinson GR, Kuritzkes DR, et al. A multi-investigator/ institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials 2003; 4:287-300.
14. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204: 1191-201.